The Global Bioprocess Validation Market size is expected to reach $650.6 Million by 2028, rising at a market growth of 8.5% CAGR during the forecast period.
The documentation of all procedures, evidence, and activities of the process of biological and biopharmaceutical product formation is known as bioprocess validation. The documentation is performed as per the guidelines of various regulatory bodies, for instance, US FDA (Food and Drug Administration).
It ensures the maintenance of compliance in all the stages of the product testing procedures. Assessing Active Pharmaceutical Ingredients (API) and impurities is essential to bioprocess validation. The primary principle of validation is to ensure that every process of the bioproduct processing is evaluated, which provides quality products, maintaining scientifically documented evidence.
Quality, efficacy, and safety are maintained during the bioprocess validation. Validation has become an essential issue in manufacturing biopharmaceuticals or biologies intended for therapeutic usage. In addition to the validation of final product quality, manufacturing process validation is gaining wide attention. Bioprocesses are sensitive and delicate and hence require careful planning and organization for successful process validation. As a result, bioprocess chromatography is the most generally utilized unit operation in biologics manufacturing.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Eurofins Scientific SE, Sartorius AG, Merck KGaA, Lonza Group AG, Danaher Corporation, Charles River Laboratories International, Inc., SGS S.A., Labcorp Corporation, and Cobetter Filtration equipment Co., Ltd.
The documentation of all procedures, evidence, and activities of the process of biological and biopharmaceutical product formation is known as bioprocess validation. The documentation is performed as per the guidelines of various regulatory bodies, for instance, US FDA (Food and Drug Administration).
It ensures the maintenance of compliance in all the stages of the product testing procedures. Assessing Active Pharmaceutical Ingredients (API) and impurities is essential to bioprocess validation. The primary principle of validation is to ensure that every process of the bioproduct processing is evaluated, which provides quality products, maintaining scientifically documented evidence.
Quality, efficacy, and safety are maintained during the bioprocess validation. Validation has become an essential issue in manufacturing biopharmaceuticals or biologies intended for therapeutic usage. In addition to the validation of final product quality, manufacturing process validation is gaining wide attention. Bioprocesses are sensitive and delicate and hence require careful planning and organization for successful process validation. As a result, bioprocess chromatography is the most generally utilized unit operation in biologics manufacturing.
COVID-19 Impact Analysis
The COVID-19 pandemic has adversely impacted the world economy due to the imposed lockdown, business shutdown, and restriction on travel. This critically affected numerous industries' manufacturing plants and factories, affecting the sales and product supply chains negatively. The rising COVID-19 infections have led to the development of precision medicines and biosimilars that raise the demands for outsourcing services and the bioprocess validation process. As a result, major market players have also started to enhance and implement the validation process for the bioprocess of biologics and drug developments. An effective validation ensures the product's safety, quality, and efficiency, which is expected further to surge the market growth of the bioprocess validation.Market Growth Factors
The rise in the need to outsource bioprocess validation
In the pharmaceutical sector, compliance with the standards of different regulatory bodies is essential, which is why bioprocess validation is an integrated process in pharmaceuticals. Validation verifies that all procedures stick to the stated requirements by the government’s regulations. Any validation method requires exhaustive documentation that conforms to standard operating procedures and ongoing activities. Pharmaceutical manufacturing is being outsourced to third-party service providers to raise production yields. The wide usage of disposable technologies in medication development aids in reducing production costs. The increasing outsourcing of bioprocesses validation to third-party service providers will propel the growth of the bioprocess validation market.Rising usage of single use bioprocessing
The implementation of single-use bioprocessing systems enhances manufacturing processes' productivity by reducing automation's cost and complexity. It also eliminates the requirement for changeover cleaning/validation between consecutive operations. In addition, single-use bioprocessing systems eliminate the need for additional investments by removing the requirement for sterilization. The initial investment costs with single-use bioprocessing systems are lower compared to that of the stainless-steel facility at the same scale, making it suitable for new players with low investments. Thereby boosting the demand for the bioprocess validation market.Market Restraining Factor
Possible issues with extractables & leachable
The food and pharmaceutical sectors are dealing with difficulties with the trace quantity of contaminants generated by the extraction or leaching process. Even after the strict regulations of many nations’ governments, corporations are still disregarding such issues and the risk to the lives of consumers/patients. Pharmaceutical manufacturers and regulatory agencies are concerned with extractable and leachable. Any containers and pharmaceutical packaging system, including plastic bottles, labeling ink, packing materials, glass, and foil pouches, can leach undesired pollutants into the food ingredient or drug products. Oral drugs, parental and ophthalmic products often pose a more eminent danger. Hence, the issues related to extractables and leachable are expected to hamper the growth of the bioprocess validation market.Testing Type Outlook
Based on testing type, the bioprocess validation market is segmented into extractables & leachables testing, bioprocess residuals testing, viral clearance testing, filtration & fermentation systems testing and others. The extractables & leachables testing segment garnered a significant revenue share in the bioprocess validation market in 2021. The growth is attributed to the presence of good manufacturing practice guidelines and US FDA regulations. Due to this, there is a huge demand for certified quality bioproducts. The biotechnology and biopharmaceutical companies are engaged in manufacturing cGMP-certified bioproducts. The requirement for government-certified products will propel the segment’s growth in the forecasted period.Stage Outlook
On the basis of stage, the bioprocess validation market is divided into process design, process qualification, and continued process verification. The continued process verification segment witnessed the largest revenue share in the bioprocess validation market in 2021. This is because it collects the processing, data collection analysis, and storage of every batch. The primary reasons for creating a continued process verification plan are to achieve compliance with regulatory bodies, prevent batch discards, and mitigate process vulnerabilities while finding constant enhancement possibilities. These features and the automation in this process will boost the segment's expansion.Mode Outlook
By mode, the bioprocess validation market is bifurcated into in house and outsourced. The outsourced segment projected a substantial revenue share in the bioprocess validation market in 2021. This is due to biopharmaceutical and biotechnology companies' high demand for testing services. There is an increase in expenditure for healthcare and the supply of raw materials needed by the market players. In addition, there is also a rising number of CDMOs (Contract Development and Manufacturing Organization) providing drug development and manufacturing services to the pharma and biopharma industries.Regional Outlook
Region-wise, the bioprocess validation market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region dominated the bioprocess validation market with the largest revenue share in 2021. This is because of significant outsourcing services providers in the region, which leads to the rise in life science research and the production of biologics. Also, the region has many FDA-approved biopharmaceuticals and biotechnological industries. The increased government funding for the bioprocess validation process and the conduct of clinical trials, combined with the presence of many key players, will surge the market’s growth in the region.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Eurofins Scientific SE, Sartorius AG, Merck KGaA, Lonza Group AG, Danaher Corporation, Charles River Laboratories International, Inc., SGS S.A., Labcorp Corporation, and Cobetter Filtration equipment Co., Ltd.
Recent Strategies Deployed in Bioprocess Validation Market
- Sep-2022: Lonza collaborated with Touchlight, a biotechnology company. With this collaboration, Lonza would have the capacity to combine a diverse, additional source of DNA in its complete suite for customers developing messenger RNA vaccines and therapeutics and at the same time Touchlight could broaden the channels through which customers can earn access to Lonza's novel doggy bone DNA (dbDNA) technology
- Aug-2022: Thermo Fisher Scientific opened a dry powder media manufacturing facility in Grand Island, New York. The new facility would offer the inessential potential to assist the global supply of media and further broadens the site's abilities to deliver the quality technology and materials required for the commercial manufacturing and development of biological and vaccine therapies
- Jun-2022: Merck collaborated with Agilent Technologies, a leader in life diagnostics, sciences, and applied chemical markets. Under this collaboration, both companies would advance bioprocess offering with Agilent’s leading analytical solutions to provide combined abilities for improved downstream process control and monitoring
- Feb-2022-Feb: Sartorius Stedim Biotech, a subgroup of Sartorius, completed the acquisition of the chromatography division of Novasep, a leading supplier of services in the field of purification and molecule production. The acquisition of a chromatography suite consists of chromatography systems suitable for smaller biomolecules and advanced systems for the continuous production of biologics
- May-2021: Eurofins BioPharma Product Testing Columbia signed an agreement with Plus Therapeutics, Inc., a clinical-stage pharmaceutical company. Through this Agreement, Eurofins would develop and validate test methods for the composition, and identity of Re-BMEDA, the active pharmaceutical ingredient (API) in RNL and purity
- Jan-2021: Sartorius collaborated with RoosterBio, Inc., a leading provider of highly engineered media, human mesenchymal stem/stromal cell working cell banks, and hMSC bioprocess systems. Under the collaboration, both companies would aim to advance the development of hMSC manufacturing of regenerative medicine by enhancing the quality solutions of both companies to notably decrease process development efforts, industrialize the supply chain and boost the development and production of better cell-based regenerative cures
- Dec-2020: Sartorius completed the acquisition WaterSep BioSeparations LLC, a U.S.-based purification expert. This acquisition aligns with the company's current suite for cell and gene therapy applications, cell harvesting, and multiple solutions for robust bioprocessing
- Apr-2020: Merck launched BioContinuum™ Platform, the Bio4C™ Software Suite, making a first-of-its-kind ecosystem that integrates process management, plant-level automation, and analytics. The launched product portfolio would enable users to view the complete manufacturing process versus particular operational units, delivering biomanufacturers comprehensive deep insights and process control
- Apr-2020: Sartorius announced the acquisition of selected life science businesses of Danaher Corporation, a globally diversified conglomerate company. This acquisition would help customers completely in the advancement of biotech medicines and vaccines, also in the protected and smooth production of the same pharmaceuticals
- May-2018: Eurofins Scientific acquired PHAST, a leading service provider in the field of pharmaceutical product quality. This acquisition would align with Eurofins’ BioPharma Product Testing abilities and broadens its geographical reach in these markets
Scope of the Study
Market Segments Covered in the Report:
By Stage
- Continued Process Verification
- Process Qualification
- Process Design
By Mode
- In House
- Outsourced
By Testing Type
- Bioprocess Residuals Testing
- Extractables & Leachables Testing
- Viral Clearance Testing
- Filtration & Fermentation Systems Testing
- Others
By Geography
North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Eurofins Scientific SE
- Sartorius AG
- Merck KGaA
- Lonza Group AG
- Danaher Corporation
- Charles River Laboratories International, Inc
- SGS S.A
- Labcorp Corporation
- Cobetter Filtration equipment Co., Ltd
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Bioprocess Validation Market, by Stage
1.4.2 Global Bioprocess Validation Market, by Mode
1.4.3 Global Bioprocess Validation Market, by Testing Type
1.4.4 Global Bioprocess Validation Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Bioprocess Validation Market
Chapter 4. Global Bioprocess Validation Market by Stage
4.1 Global Continued Process Verification Market by Region
4.2 Global Process Qualification Market by Region
4.3 Global Process Design Market by Region
Chapter 5. Global Bioprocess Validation Market by Mode
5.1 Global In House Market by Region
5.2 Global Outsourced Market by Region
Chapter 6. Global Bioprocess Validation Market by Testing Type
6.1 Global Bioprocess Residuals Testing Market by Region
6.2 Global Extractables & Leachables Testing Market by Region
6.3 Global Viral Clearance Testing Market by Region
6.4 Global Filtration & Fermentation Systems Testing Market by Region
6.5 Global Others Market by Region
Chapter 7. Global Bioprocess Validation Market by Region
7.1 North America Bioprocess Validation Market
7.1.1 North America Bioprocess Validation Market by Stage
7.1.1.1 North America Continued Process Verification Market by Country
7.1.1.2 North America Process Qualification Market by Country
7.1.1.3 North America Process Design Market by Country
7.1.2 North America Bioprocess Validation Market by Mode
7.1.2.1 North America In House Market by Country
7.1.2.2 North America Outsourced Market by Country
7.1.3 North America Bioprocess Validation Market by Testing Type
7.1.3.1 North America Bioprocess Residuals Testing Market by Country
7.1.3.2 North America Extractables & Leachables Testing Market by Country
7.1.3.3 North America Viral Clearance Testing Market by Country
7.1.3.4 North America Filtration & Fermentation Systems Testing Market by Country
7.1.3.5 North America Others Market by Country
7.1.4 North America Bioprocess Validation Market by Country
7.1.4.1 US Bioprocess Validation Market
7.1.4.1.1 US Bioprocess Validation Market by Stage
7.1.4.1.2 US Bioprocess Validation Market by Mode
7.1.4.1.3 US Bioprocess Validation Market by Testing Type
7.1.4.2 Canada Bioprocess Validation Market
7.1.4.2.1 Canada Bioprocess Validation Market by Stage
7.1.4.2.2 Canada Bioprocess Validation Market by Mode
7.1.4.2.3 Canada Bioprocess Validation Market by Testing Type
7.1.4.3 Mexico Bioprocess Validation Market
7.1.4.3.1 Mexico Bioprocess Validation Market by Stage
7.1.4.3.2 Mexico Bioprocess Validation Market by Mode
7.1.4.3.3 Mexico Bioprocess Validation Market by Testing Type
7.1.4.4 Rest of North America Bioprocess Validation Market
7.1.4.4.1 Rest of North America Bioprocess Validation Market by Stage
7.1.4.4.2 Rest of North America Bioprocess Validation Market by Mode
7.1.4.4.3 Rest of North America Bioprocess Validation Market by Testing Type
7.2 Europe Bioprocess Validation Market
7.2.1 Europe Bioprocess Validation Market by Stage
7.2.1.1 Europe Continued Process Verification Market by Country
7.2.1.2 Europe Process Qualification Market by Country
7.2.1.3 Europe Process Design Market by Country
7.2.2 Europe Bioprocess Validation Market by Mode
7.2.2.1 Europe In House Market by Country
7.2.2.2 Europe Outsourced Market by Country
7.2.3 Europe Bioprocess Validation Market by Testing Type
7.2.3.1 Europe Bioprocess Residuals Testing Market by Country
7.2.3.2 Europe Extractables & Leachables Testing Market by Country
7.2.3.3 Europe Viral Clearance Testing Market by Country
7.2.3.4 Europe Filtration & Fermentation Systems Testing Market by Country
7.2.3.5 Europe Others Market by Country
7.2.4 Europe Bioprocess Validation Market by Country
7.2.4.1 Germany Bioprocess Validation Market
7.2.4.1.1 Germany Bioprocess Validation Market by Stage
7.2.4.1.2 Germany Bioprocess Validation Market by Mode
7.2.4.1.3 Germany Bioprocess Validation Market by Testing Type
7.2.4.2 UK Bioprocess Validation Market
7.2.4.2.1 UK Bioprocess Validation Market by Stage
7.2.4.2.2 UK Bioprocess Validation Market by Mode
7.2.4.2.3 UK Bioprocess Validation Market by Testing Type
7.2.4.3 France Bioprocess Validation Market
7.2.4.3.1 France Bioprocess Validation Market by Stage
7.2.4.3.2 France Bioprocess Validation Market by Mode
7.2.4.3.3 France Bioprocess Validation Market by Testing Type
7.2.4.4 Russia Bioprocess Validation Market
7.2.4.4.1 Russia Bioprocess Validation Market by Stage
7.2.4.4.2 Russia Bioprocess Validation Market by Mode
7.2.4.4.3 Russia Bioprocess Validation Market by Testing Type
7.2.4.5 Spain Bioprocess Validation Market
7.2.4.5.1 Spain Bioprocess Validation Market by Stage
7.2.4.5.2 Spain Bioprocess Validation Market by Mode
7.2.4.5.3 Spain Bioprocess Validation Market by Testing Type
7.2.4.6 Italy Bioprocess Validation Market
7.2.4.6.1 Italy Bioprocess Validation Market by Stage
7.2.4.6.2 Italy Bioprocess Validation Market by Mode
7.2.4.6.3 Italy Bioprocess Validation Market by Testing Type
7.2.4.7 Rest of Europe Bioprocess Validation Market
7.2.4.7.1 Rest of Europe Bioprocess Validation Market by Stage
7.2.4.7.2 Rest of Europe Bioprocess Validation Market by Mode
7.2.4.7.3 Rest of Europe Bioprocess Validation Market by Testing Type
7.3 Asia Pacific Bioprocess Validation Market
7.3.1 Asia Pacific Bioprocess Validation Market by Stage
7.3.1.1 Asia Pacific Continued Process Verification Market by Country
7.3.1.2 Asia Pacific Process Qualification Market by Country
7.3.1.3 Asia Pacific Process Design Market by Country
7.3.2 Asia Pacific Bioprocess Validation Market by Mode
7.3.2.1 Asia Pacific In House Market by Country
7.3.2.2 Asia Pacific Outsourced Market by Country
7.3.3 Asia Pacific Bioprocess Validation Market by Testing Type
7.3.3.1 Asia Pacific Bioprocess Residuals Testing Market by Country
7.3.3.2 Asia Pacific Extractables & Leachables Testing Market by Country
7.3.3.3 Asia Pacific Viral Clearance Testing Market by Country
7.3.3.4 Asia Pacific Filtration & Fermentation Systems Testing Market by Country
7.3.3.5 Asia Pacific Others Market by Country
7.3.4 Asia Pacific Bioprocess Validation Market by Country
7.3.4.1 China Bioprocess Validation Market
7.3.4.1.1 China Bioprocess Validation Market by Stage
7.3.4.1.2 China Bioprocess Validation Market by Mode
7.3.4.1.3 China Bioprocess Validation Market by Testing Type
7.3.4.2 Japan Bioprocess Validation Market
7.3.4.2.1 Japan Bioprocess Validation Market by Stage
7.3.4.2.2 Japan Bioprocess Validation Market by Mode
7.3.4.2.3 Japan Bioprocess Validation Market by Testing Type
7.3.4.3 India Bioprocess Validation Market
7.3.4.3.1 India Bioprocess Validation Market by Stage
7.3.4.3.2 India Bioprocess Validation Market by Mode
7.3.4.3.3 India Bioprocess Validation Market by Testing Type
7.3.4.4 South Korea Bioprocess Validation Market
7.3.4.4.1 South Korea Bioprocess Validation Market by Stage
7.3.4.4.2 South Korea Bioprocess Validation Market by Mode
7.3.4.4.3 South Korea Bioprocess Validation Market by Testing Type
7.3.4.5 Singapore Bioprocess Validation Market
7.3.4.5.1 Singapore Bioprocess Validation Market by Stage
7.3.4.5.2 Singapore Bioprocess Validation Market by Mode
7.3.4.5.3 Singapore Bioprocess Validation Market by Testing Type
7.3.4.6 Malaysia Bioprocess Validation Market
7.3.4.6.1 Malaysia Bioprocess Validation Market by Stage
7.3.4.6.2 Malaysia Bioprocess Validation Market by Mode
7.3.4.6.3 Malaysia Bioprocess Validation Market by Testing Type
7.3.4.7 Rest of Asia Pacific Bioprocess Validation Market
7.3.4.7.1 Rest of Asia Pacific Bioprocess Validation Market by Stage
7.3.4.7.2 Rest of Asia Pacific Bioprocess Validation Market by Mode
7.3.4.7.3 Rest of Asia Pacific Bioprocess Validation Market by Testing Type
7.4 LAMEA Bioprocess Validation Market
7.4.1 LAMEA Bioprocess Validation Market by Stage
7.4.1.1 LAMEA Continued Process Verification Market by Country
7.4.1.2 LAMEA Process Qualification Market by Country
7.4.1.3 LAMEA Process Design Market by Country
7.4.2 LAMEA Bioprocess Validation Market by Mode
7.4.2.1 LAMEA In House Market by Country
7.4.2.2 LAMEA Outsourced Market by Country
7.4.3 LAMEA Bioprocess Validation Market by Testing Type
7.4.3.1 LAMEA Bioprocess Residuals Testing Market by Country
7.4.3.2 LAMEA Extractables & Leachables Testing Market by Country
7.4.3.3 LAMEA Viral Clearance Testing Market by Country
7.4.3.4 LAMEA Filtration & Fermentation Systems Testing Market by Country
7.4.3.5 LAMEA Others Market by Country
7.4.4 LAMEA Bioprocess Validation Market by Country
7.4.4.1 Brazil Bioprocess Validation Market
7.4.4.1.1 Brazil Bioprocess Validation Market by Stage
7.4.4.1.2 Brazil Bioprocess Validation Market by Mode
7.4.4.1.3 Brazil Bioprocess Validation Market by Testing Type
7.4.4.2 Argentina Bioprocess Validation Market
7.4.4.2.1 Argentina Bioprocess Validation Market by Stage
7.4.4.2.2 Argentina Bioprocess Validation Market by Mode
7.4.4.2.3 Argentina Bioprocess Validation Market by Testing Type
7.4.4.3 UAE Bioprocess Validation Market
7.4.4.3.1 UAE Bioprocess Validation Market by Stage
7.4.4.3.2 UAE Bioprocess Validation Market by Mode
7.4.4.3.3 UAE Bioprocess Validation Market by Testing Type
7.4.4.4 Saudi Arabia Bioprocess Validation Market
7.4.4.4.1 Saudi Arabia Bioprocess Validation Market by Stage
7.4.4.4.2 Saudi Arabia Bioprocess Validation Market by Mode
7.4.4.4.3 Saudi Arabia Bioprocess Validation Market by Testing Type
7.4.4.5 South Africa Bioprocess Validation Market
7.4.4.5.1 South Africa Bioprocess Validation Market by Stage
7.4.4.5.2 South Africa Bioprocess Validation Market by Mode
7.4.4.5.3 South Africa Bioprocess Validation Market by Testing Type
7.4.4.6 Nigeria Bioprocess Validation Market
7.4.4.6.1 Nigeria Bioprocess Validation Market by Stage
7.4.4.6.2 Nigeria Bioprocess Validation Market by Mode
7.4.4.6.3 Nigeria Bioprocess Validation Market by Testing Type
7.4.4.7 Rest of LAMEA Bioprocess Validation Market
7.4.4.7.1 Rest of LAMEA Bioprocess Validation Market by Stage
7.4.4.7.2 Rest of LAMEA Bioprocess Validation Market by Mode
7.4.4.7.3 Rest of LAMEA Bioprocess Validation Market by Testing Type
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Geographical Expansions:
8.1.6 SWOT Analysis
8.2 Eurofins Scientific SE
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.4.2 Acquisition and Mergers:
8.3 Sartorius AG
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Merck KGaA
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.5 Lonza Group AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Danaher Corporation
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.7 Charles River Laboratories International, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.8 SGS S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.9 Labcorp Corporation
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.10. Cobetter Filtration equipment Co., Ltd.
8.10.1 Company Overview
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific SE
- Sartorius AG
- Merck KGaA
- Lonza Group AG
- Danaher Corporation
- Charles River Laboratories International, Inc.
- SGS S.A.
- Labcorp Corporation
- Cobetter Filtration equipment Co., Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 221 |
| Published | January 2023 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 375.1 Million |
| Forecasted Market Value ( USD | $ 650.6 Million |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
